Nerre Therapeutics

Developing clinical and pre-clinical neurokinin receptor antagonists

placeStevenage, England, United Kingdom calendar_todayFounded 2012 groups14 employees language nerretherapeutics.com

Registered entities

Innovation

15 patent families (11 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 729 times.

YearFilings
20145
20155
20163
20177
20186
20193
20205
20219
20223
20234
20241
20252

Investor mix

7 investors on record; lead investors include Columbus Venture Partners.

Investor typeCountShare
Venture capital571%
Other / undisclosed229%
Coming soon